All Stories

  1. S1200 Characterization of Hospitalized Patients With Ulcerative Colitis Treated With Tofacitinib in the OCTAVE Clinical Program for up to 7.8 Years

    Article • The American Journal of Gastroenterology, October 2023, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  2. Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: A systematic review and meta-analysis

    Article • June 2023, Peeref

    MD. PhD. Carlos Taxonera

  3. 603 VEDOLIZUMAB PREVENTS POSTOPERATIVE REUCURRENCE IN CROHN'S DISEASE: RESULTS OF THE REPREVIO TRIAL

    Article • Gastroenterology, May 2023, Elsevier

    MD. PhD. Carlos Taxonera

  4. Tu1770 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Article • Gastroenterology, May 2023, Elsevier

    MD. PhD. Carlos Taxonera

  5. 119 - FACTORES PREDICTIVOS DE RESPUESTA A FILGOTINIB EN COLITIS ULCEROSA: ANÁLISIS POST HOC DEL ESTUDIO SELECTION

    Article • Gastroenterología y Hepatología, March 2023, Elsevier

    MD. PhD. Carlos Taxonera

  6. OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO

    Article • Journal of Crohn s and Colitis, January 2023, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  7. P525 Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysis

    Article • Journal of Crohn s and Colitis, January 2023, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  8. P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years

    Article • Journal of Crohn s and Colitis, January 2023, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  9. Real-world confirmed effectiveness and safety of ustekinumab in patients with ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, January 2023, Wiley

    MD. PhD. Carlos Taxonera

  10. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Article • Journal of Clinical Medicine, December 2022, MDPI AG

    MD. PhD. Carlos Taxonera

  11. Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis—Author’s reply

    Article • Alimentary Pharmacology & Therapeutics, July 2022, Wiley

    MD. PhD. Carlos Taxonera

  12. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, May 2022, Wiley

    MD. PhD. Carlos Taxonera

  13. Mo1534: ASSOCIATION OF GOLIMUMAB TROUGH CONCENTRATIONS DURING MAINTENANCE WITH ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS.

    Article • Gastroenterology, May 2022, Elsevier

    MD. PhD. Carlos Taxonera

  14. Su1496: SARS-COV-2 INFECTION IN IBD: PANDEMIC WAVES AND PREDICTORS OF SEVERE OR PERSISTENT COVID-19

    Article • Gastroenterology, May 2022, Elsevier

    MD. PhD. Carlos Taxonera

  15. Diagnosis and treatment of Inflammatory Bowel Disease in 2022

    Article • ANALES RANM, April 2022, Royal Spanish Academy of Medicine

    MD. PhD. Carlos Taxonera

  16. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Article • Biomedicines, March 2022, MDPI AG

    MD. PhD. Carlos Taxonera

  17. Editorial: real‐world safety of tofacitinib in ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, January 2022, Wiley

    MD. PhD. Carlos Taxonera

  18. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Article • Journal of Clinical Medicine, January 2022, MDPI AG

    MD. PhD. Carlos Taxonera

  19. Clinical settings with tofacitinib in ulcerative colitis

    Article • Revista Española de Enfermedades Digestivas, January 2022, Sociedad Espanola de Patologia Digestiva (SEPD)

    MD. PhD. Carlos Taxonera

  20. P114 SARS-CoV-2 infection in IBD: pandemic waves and predictors of severe or persistent COVID-19

    Article • Journal of Crohn s and Colitis, January 2022, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  21. P292 Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis

    Article • Journal of Crohn s and Colitis, January 2022, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  22. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

    Article • The Lancet Gastroenterology & Hepatology, November 2021, Elsevier

    Charles Murray, MD. PhD. Carlos Taxonera

  23. Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings

    Article • Rheumatology International, August 2021, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  24. Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review–Authors’ Reply

    Article • Inflammatory Bowel Diseases, May 2021, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  25. P355 Preferences and satisfaction of IBD patients in whom the adalimumab regimen was changed from 40 mg weekly to 80 mg every other week: the ADASCAL study

    Article • Journal of Crohn s and Colitis, May 2021, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  26. What Is the Incidence of COVID-19 in Patients With IBD in Western Countries?

    Article • Gastroenterology, April 2021, Elsevier

    MD. PhD. Carlos Taxonera

  27. Can COVID-19 Trigger De Novo Inflammatory Bowel Disease?

    Article • Gastroenterology, March 2021, Elsevier

    MD. PhD. Carlos Taxonera

  28. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, February 2021, Taylor & Francis

    MD. PhD. Carlos Taxonera

  29. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis

    Article • Inflammatory Bowel Diseases, February 2021, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  30. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la infección tuberculosa en pacientes con enfermedad inflamatoria intestinal

    Article • Gastroenterología y Hepatología, January 2021, Elsevier

    MD. PhD. Carlos Taxonera

  31. ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation

    Article • Revista Española de Enfermedades Digestivas, January 2021, Sociedad Espanola de Patologia Digestiva (SEPD)

    MD. PhD. Carlos Taxonera

  32. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease

    Article • Gastroenterología y Hepatología (English Edition), January 2021, Elsevier

    MD. PhD. Carlos Taxonera

  33. Letter: SARS‐CoV‐2 induced gastrointestinal inflammation—authors' reply

    Article • Alimentary Pharmacology & Therapeutics, November 2020, Wiley

    MD. PhD. Carlos Taxonera

  34. Long-term survey of sea turtles (Caretta caretta) reveals correlations between parasite infection, feeding ecology, reproductive success and population dynamics

    Article • Scientific Reports, October 2020, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  35. Distribution of genetic diversity reveals colonization patterns and philopatry of the loggerhead sea turtles across geographic scales

    Article • Scientific Reports, October 2020, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  36. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

    Article • Scientific Reports, October 2020, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  37. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry

    Article • Journal of Crohn s and Colitis, September 2020, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  38. Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France. Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, September 2020, Wiley

    MD. PhD. Carlos Taxonera

  39. Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures

    Article • Inflammatory Bowel Diseases, August 2020, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  40. Letter: immunotherapy for IBD patients in a SARS-CoV-2 endemic area-authors' reply

    Article • Alimentary Pharmacology & Therapeutics, August 2020, Wiley

    MD. PhD. Carlos Taxonera

  41. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry

    Article • Alimentary Pharmacology & Therapeutics, August 2020, Wiley

    MD. PhD. Carlos Taxonera

  42. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis

    Article • Clinical and Translational Gastroenterology, August 2020, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  43. Editorial: social distancing during the COVID-19 pandemic-IBD patients cannot stay at home forever. Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, July 2020, Wiley

    MD. PhD. Carlos Taxonera

  44. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, June 2020, Wiley

    MD. PhD. Carlos Taxonera

  45. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

    Article • Alimentary Pharmacology & Therapeutics, June 2020, Wiley

    MD. PhD. Carlos Taxonera

  46. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

    Article • Journal of Gastroenterology and Hepatology, May 2020, Wiley

    MD. PhD. Carlos Taxonera

  47. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease

    Article • European Journal of Gastroenterology & Hepatology, May 2020, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  48. Tu1904 USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM ENEIDA REGISTRY

    Article • Gastroenterology, May 2020, Elsevier

    MD. PhD. Carlos Taxonera

  49. Mo1860 REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY

    Article • Gastroenterology, May 2020, Elsevier

    MD. PhD. Carlos Taxonera

  50. Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry

    Article • Journal of Crohn s and Colitis, March 2020, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  51. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease

    Article • Alimentary Pharmacology & Therapeutics, March 2020, Wiley

    MD. PhD. Carlos Taxonera

  52. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review

    Article • Therapeutic Advances in Gastroenterology, January 2020, SAGE Publications

    MD. PhD. Carlos Taxonera

  53. PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN

    Article • Value in Health, November 2019, Elsevier

    MD. PhD. Carlos Taxonera

  54. PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

    Article • Value in Health, November 2019, Elsevier

    MD. PhD. Carlos Taxonera

  55. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

    Article • Journal of Crohn s and Colitis, October 2019, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  56. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

    Article • Inflammatory Bowel Diseases, August 2019, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  57. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Article • Alimentary Pharmacology & Therapeutics, August 2019, Wiley

    MD. PhD. Carlos Taxonera

  58. Management and outcomes of patients with Crohn’s disease with first vs multiple surgeries: results from the PRACTICROHN study

    Article • Gastroenterology Report, July 2019, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  59. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

    Article • Alimentary Pharmacology & Therapeutics, June 2019, Wiley

    MD. PhD. Carlos Taxonera

  60. Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study

    Article • Expert Review of Gastroenterology & Hepatology, June 2019, Taylor & Francis

    MD. PhD. Carlos Taxonera

  61. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Article • Journal of Crohn s and Colitis, May 2019, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  62. Mo1765 – Real-Life Experience with Long-Term Maintenance of Golimumab in Ulcerative Colitis Patients

    Article • Gastroenterology, May 2019, Elsevier

    MD. PhD. Carlos Taxonera

  63. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry

    Article • Inflammatory Bowel Diseases, April 2019, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  64. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn’s patients: Results of the APPRECIA trial

    Article • Digestive and Liver Disease, April 2019, Elsevier

    MD. PhD. Carlos Taxonera

  65. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

    Article • Current Medical Research and Opinion, February 2019, Taylor & Francis

    MD. PhD. Carlos Taxonera

  66. P559 Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients

    Article • Journal of Crohn s and Colitis, January 2019, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  67. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Article • Alimentary Pharmacology & Therapeutics, January 2019, Wiley

    MD. PhD. Carlos Taxonera

  68. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Article • Therapeutic Advances in Gastroenterology, January 2019, SAGE Publications

    MD. PhD. Carlos Taxonera

  69. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Article • Therapeutic Advances in Gastroenterology, January 2019, SAGE Publications

    MD. PhD. Carlos Taxonera

  70. Differences in the need for adalimumab dose optimization between Crohn�s disease and ulcerative colitis

    Article • Revista Española de Enfermedades Digestivas, January 2019, Sociedad Espanola de Patologia Digestiva (SEPD)

    MD. PhD. Carlos Taxonera

  71. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Article • Digestive Diseases and Sciences, November 2018, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  72. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

    Article • Alimentary Pharmacology & Therapeutics, October 2018, Wiley

    MD. PhD. Carlos Taxonera

  73. Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico

    Article • Actas Dermo-Sifiliográficas, September 2018, Elsevier

    MD. PhD. Carlos Taxonera

  74. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

    Article • Actas Dermo-Sifiliográficas (English Edition), September 2018, Elsevier

    MD. PhD. Carlos Taxonera

  75. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease

    Article • Journal of Crohn s and Colitis, July 2018, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  76. Mo1861 - Long-Term Safety of Adalimumab in Patients with Moderate to Severe Ulcerative Colitis: Interim Results of a Noninterventional Registry, Legacy

    Article • Gastroenterology, May 2018, Elsevier

    MD. PhD. Carlos Taxonera

  77. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

    Article • The American Journal of Gastroenterology, March 2018, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  78. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial

    Article • Journal of Crohn s and Colitis, February 2018, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  79. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis

    Article • Digestive Diseases and Sciences, January 2018, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  80. DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY

    Article • Journal of Crohn s and Colitis, January 2018, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  81. P674 Clinical characteristics and management of Crohn’s disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study

    Article • Journal of Crohn s and Colitis, January 2018, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  82. P686 Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: PRACTICROHN study

    Article • Journal of Crohn s and Colitis, January 2018, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  83. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels

    Article • Therapeutic Advances in Gastroenterology, January 2018, SAGE Publications

    MD. PhD. Carlos Taxonera

  84. Eosinophilic colitis: Case series and literature review

    Article • Pathology - Research and Practice, January 2018, Elsevier

    MD. PhD. Carlos Taxonera

  85. Incidence and Management of Recurrence in Patients with Crohnʼs Disease Who Have Undergone Intestinal Resection

    Article • Inflammatory Bowel Diseases, October 2017, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  86. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, August 2017, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  87. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn’s Disease Recurrence. A GETECCU Randomised Trial

    Article • Journal of Crohn s and Colitis, April 2017, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  88. Serial Tuberculin Skin Test Improves the Detection of Latent Tuberculosis Infection in Inflammatory Bowel Disease Patients

    Article • Gastroenterology, April 2017, Elsevier

    MD. PhD. Carlos Taxonera

  89. Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease

    Article • Journal of Crohn s and Colitis, February 2017, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  90. DOP039 Postoperative infectious complications in Crohn's disease: results from PRACTICROHN study

    Article • Journal of Crohn s and Colitis, January 2017, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  91. P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease

    Article • Journal of Crohn s and Colitis, January 2017, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  92. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    Article • The American Journal of Gastroenterology, January 2017, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  93. Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn’s disease

    Article • Revista Española de Enfermedades Digestivas, January 2017, Sociedad Espanola de Patologia Digestiva (SEPD)

    MD. PhD. Carlos Taxonera

  94. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

    Article • Digestive Diseases and Sciences, December 2016, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  95. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab

    Article • Biochemical Pharmacology, December 2016, Elsevier

    MD. PhD. Carlos Taxonera

  96. Ustekinumab for the Treatment of Refractory Crohnʼs Disease

    Article • Inflammatory Bowel Diseases, July 2016, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  97. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent

    Article • Digestive and Liver Disease, June 2016, Elsevier

    MD. PhD. Carlos Taxonera

  98. Corrigendum: Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study

    Article • The American Journal of Gastroenterology, June 2016, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  99. Sa1914 Long-Term Outcomes of a Cohort of Crohn's Disease Patients With Idiopathic Lymphopenia

    Article • Gastroenterology, April 2016, Elsevier

    MD. PhD. Carlos Taxonera

  100. Sa1955 Comparison of Four Assay Kits for Measuring Infliximab Trough Levels and Antibodies to Infliximab in Patients With Inflammatory Bowel Disease

    Article • Gastroenterology, April 2016, Elsevier

    MD. PhD. Carlos Taxonera

  101. Sa1973 Loss of Anti-TNF Drugs Into Feces and Its Impact on Anti- TNF Serum Levels and Clinical Response in Crohn's Disease (CD) Patients

    Article • Gastroenterology, April 2016, Elsevier

    MD. PhD. Carlos Taxonera

  102. Su1008 Health-Related Quality of Life Improves During One Year of Postoperative Prophylactic Drug Therapy After Ileocecal Intestinal Resection in Crohn's Disease Patients: Results of the APPRECIA Randomized Trial

    Article • Gastroenterology, April 2016, Elsevier

    MD. PhD. Carlos Taxonera

  103. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, March 2016, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  104. P-044 Outcomes of Tuberculin Skin Test in Routine Screening for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases

    Article • Inflammatory Bowel Diseases, March 2016, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  105. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study

    Article • The American Journal of Gastroenterology, February 2016, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  106. Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn’s Disease

    Article • Journal of Crohn s and Colitis, January 2016, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  107. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment

    Article • Archivos de Bronconeumología (English Edition), January 2016, Elsevier

    MD. PhD. Carlos Taxonera

  108. Specialist care in the management of inflammatory bowel disease

    Article • Revista Española de Enfermedades Digestivas, January 2016, Sociedad Espanola de Patologia Digestiva (SEPD)

    MD. PhD. Carlos Taxonera

  109. Documento de consenso sobre la prevención y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico

    Article • Archivos de Bronconeumología, January 2016, Elsevier

    MD. PhD. Carlos Taxonera

  110. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal

    Article • Enfermedad Inflamatoria Intestinal al Día, September 2015, Elsevier

    MD. PhD. Carlos Taxonera

  111. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

    Article • Digestive Diseases and Sciences, June 2015, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  112. FP484GRANULOCYTE APHERESIS IN REFRACTORY ULCERATIVE COLITIS: COMPARISON BETWEEN TWO THERAPEUTIC REGIMENS

    Article • Nephrology Dialysis Transplantation, May 2015, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  113. Tu1113 Endoscopic and Histologic Remission Correlation With Biomarkers in UC Patients Treated With Adalimumab

    Article • Gastroenterology, April 2015, Elsevier

    MD. PhD. Carlos Taxonera

  114. Tu1107 Adalimumab Dose Escalation Is Effective for Managing Loss of Response in Ulcerative Colitis

    Article • Gastroenterology, April 2015, Elsevier

    MD. PhD. Carlos Taxonera

  115. Incidence, Management, and Course of Cancer in Patients with Inflammatory Bowel Disease

    Article • Journal of Crohn s and Colitis, February 2015, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  116. Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

    Article • Mediators of Inflammation, January 2015, Hindawi Publishing Corporation

    MD. PhD. Carlos Taxonera

  117. P-064 Adalimumab Achieves Mucosal and Histological Healing in Adult Patients With Moderate to Severe Ulcerative Colitis Naive to Anti-TNFα Treatment

    Article • Inflammatory Bowel Diseases, December 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  118. 210 Management and Course of Inflammatory Bowel Disease Patients With Associated Cancer

    Article • Gastroenterology, May 2014, Elsevier

    MD. PhD. Carlos Taxonera

  119. Mo1257 Outcomes of Surgical Treatment of Entero-Urinary Fistulas in Crohn's Disease

    Article • Gastroenterology, May 2014, Elsevier

    MD. PhD. Carlos Taxonera

  120. Sa1224 Usefulness of a Faecal Calprotectin Rapid Semiquantitative Test in Predicting Relapse in Patients With Ulcerative Colitis in Remission

    Article • Gastroenterology, May 2014, Elsevier

    MD. PhD. Carlos Taxonera

  121. Tu1175 Incidence and Characteristics of Intestinal and Extraintestinal Cancers in Patients With Inflammatory Bowel Disease: A Population-Based Study

    Article • Gastroenterology, May 2014, Elsevier

    MD. PhD. Carlos Taxonera

  122. Tu1938 Identification of New Genetic Variants Related to Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD) Patients With Normal Thiopurines-Methyltransferase (TPMT): A Genome-Wide Association Study

    Article • Gastroenterology, May 2014, Elsevier

    MD. PhD. Carlos Taxonera

  123. DOP072 Management and course of inflammatory bowel disease patients with associated cancer

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  124. P307 Treatment preferences of patients with Crohn's disease candidates for anti-TNF treatment. A conjoint analysis (IMPLICA study)

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  125. P396 Outcomes of surgical treatment of entero-urinary fistulas in Crohn's disease

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  126. P413 Management of ulcerative colitis patients in clinical practice: results of a nationwide survey (CROSSOVER) conducted in Spain

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  127. P614 Incidences and characteristics of intestinal and extraintestinal cancers in patients with inflammatory bowel disease: a population-based study

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  128. DOP051 Usefulness of a faecal calprotectin rapid semiquantitative test in predicting relapse in patients with ulcerative colitis in remission

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  129. Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab

    Article • Human Immunology, January 2014, Elsevier

    MD. PhD. Carlos Taxonera

  130. Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease

    Article • Gastroenterology, October 2013, Elsevier

    MD. PhD. Carlos Taxonera

  131. Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

    Article • Digestive Diseases and Sciences, September 2013, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  132. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study

    Article • Digestive and Liver Disease, September 2013, Elsevier

    MD. PhD. Carlos Taxonera

  133. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

    Article • Alimentary Pharmacology & Therapeutics, August 2013, Wiley

    MD. PhD. Carlos Taxonera

  134. Mo1383 Entero-Urinary Fistulas in Crohn's Disease: Prevalence and Clinical Manifestations

    Article • Gastroenterology, May 2013, Elsevier

    MD. PhD. Carlos Taxonera

  135. 951 Effectiveness of Anti-TNF Agents in the Treatment of Entero-Urinary Fistulas in Crohn's Disease

    Article • Gastroenterology, May 2013, Elsevier

    MD. PhD. Carlos Taxonera

  136. Mo1343 Inflammatory Bowel Disease Unclassified in Real Practice: Prevalence, Clinical Course and Therapy Requirements

    Article • Gastroenterology, May 2013, Elsevier

    MD. PhD. Carlos Taxonera

  137. Su1752 Identification of New Genetic Variants Related to Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD) Patients With Normal Thiopurines-Methyltransferase (TPMT): A Genome-Wide Association Study

    Article • Gastroenterology, May 2013, Elsevier

    MD. PhD. Carlos Taxonera

  138. Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease

    Article • The American Journal of Gastroenterology, March 2013, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  139. P216 Inflammatory bowel disease unclassified (IBDU) in real practice: prevalence, clinical course and therapy requirements

    Article • Journal of Crohn s and Colitis, February 2013, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  140. P650 Entero-urinary fistulas in Crohn's disease: prevalence and clinical manifestations

    Article • Journal of Crohn s and Colitis, February 2013, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  141. P536 Effectiveness of the available therapeutic options in the treatment of perianal fistulas in patients with Crohn's disease (CD)

    Article • Journal of Crohn s and Colitis, February 2013, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  142. Letter: recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings

    Article • Alimentary Pharmacology & Therapeutics, January 2013, Wiley

    MD. PhD. Carlos Taxonera

  143. Using of magnetic resonance enterography in the management of Crohn's disease of the small intestine: First year of experience

    Article • Revista Española de Enfermedades Digestivas, December 2012, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  144. Methotrexate in inflammatory bowel disease

    Article • European Journal of Gastroenterology & Hepatology, September 2012, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  145. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

    Article • Journal of Crohn s and Colitis, June 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  146. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease

    Article • Journal of Crohn s and Colitis, May 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  147. Mo1712 How Frequent are Conversions of Tuberculosis (TBC) Screening Tests Among Inflammatory Bowel Disease (IBD) Patients Under Anti-TNF Treatment?

    Article • Gastroenterology, May 2012, Elsevier

    MD. PhD. Carlos Taxonera

  148. Sa1888 Need for Infliximab Dose Intensification in Patients With Crohns Disease and Ulcerative Colitis

    Article • Gastroenterology, May 2012, Elsevier

    MD. PhD. Carlos Taxonera

  149. Sa1902 Short- and Long-Term Outcomes of Infliximab Dose Intensification in Patients With Ulcerative Colitis

    Article • Gastroenterology, May 2012, Elsevier

    MD. PhD. Carlos Taxonera

  150. Genital fistulas in female Crohn's disease patients.

    Article • Journal of Crohn s and Colitis, April 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  151. N001 Perceived quality of care received by patient attending an IBD unit

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  152. P121 Specialized IBD management at emergency room limits the need for hospital admission in IBD patients

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  153. P167 How frequent are conversions of tuberculosis (TBC) screening tests among inflammatory bowel disease (IBD) patients under anti-TNF treatment?

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  154. P352 Need for infliximab dose intensification in patients with Crohn's disease and ulcerative colitis

    Article • Journal of Crohn s and Colitis, February 2012, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  155. Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial

    Article • Scandinavian Journal of Gastroenterology, January 2012, Taylor & Francis

    MD. PhD. Carlos Taxonera

  156. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy

    Article • European Journal of Internal Medicine, December 2011, Elsevier

    MD. PhD. Carlos Taxonera

  157. Likelihood of detecting latent tuberculosis infection before and during infliximab therapy

    Article • Inflammatory Bowel Diseases, December 2011, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  158. Differential association of two PTPN22 coding variants with Crohnʼs disease and ulcerative colitis

    Article • Inflammatory Bowel Diseases, November 2011, Wolters Kluwer Health

    Dr Ad A van Bodegraven, MD. PhD. Carlos Taxonera

  159. Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis

    Article • Human Immunology, October 2011, Elsevier

    MD. PhD. Carlos Taxonera

  160. TLR9 and IL23R Genetic Interaction Modulates Crohn'S Disease Susceptibility

    Article • Gastroenterology, May 2011, Elsevier

    MD. PhD. Carlos Taxonera

  161. Association of Susceptibility Variants With Non-Perianal Crohn's Disease-Related Surgery

    Article • Gastroenterology, May 2011, Elsevier

    MD. PhD. Carlos Taxonera

  162. Decreasing Rates of Hospital Admissions for Inflammatory Bowel Disease Between 2000 and 2009

    Article • Gastroenterology, May 2011, Elsevier

    MD. PhD. Carlos Taxonera

  163. Epidemiological Study of Perianal Fistulas in Patients With Crohn's Disease

    Article • Gastroenterology, May 2011, Elsevier

    MD. PhD. Carlos Taxonera

  164. Serial Tuberculin Skin Tests to Detect Latent Tuberculosis in Inflammatory Bowel Disease Patients Receiving Infliximab Therapy

    Article • Gastroenterology, May 2011, Elsevier

    MD. PhD. Carlos Taxonera

  165. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

    Article • Alimentary Pharmacology & Therapeutics, December 2010, Wiley

    MD. PhD. Carlos Taxonera

  166. Outcomes of Pregnancies Fathered by Inflammatory Bowel Disease Patients Exposed to Thiopurines

    Article • The American Journal of Gastroenterology, September 2010, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  167. Study of chromosomal region 5p13.1 in Crohn's disease, ulcerative colitis, and rheumatoid arthritis

    Article • Human Immunology, August 2010, Elsevier

    MD. PhD. Carlos Taxonera

  168. W1291 Adalimumab in the Prevention of Postoperative Recurrence of Crohn's Disease

    Article • Gastroenterology, May 2010, Elsevier

    MD. PhD. Carlos Taxonera

  169. 409 Adalimumab for Ulcerative Colitis Patients Previously Treated With Infliximab: Outcomes at Short and Long Term and Predictors of Response

    Article • Gastroenterology, May 2010, Elsevier

    MD. PhD. Carlos Taxonera

  170. W1273 Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD): A Multicenter Study

    Article • Gastroenterology, May 2010, Elsevier

    MD. PhD. Carlos Taxonera

  171. High prevalence of viableMycobacterium aviumsubspeciesparatuberculosisin Crohn’s disease

    Article • World Journal of Gastroenterology, January 2010, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    MD. PhD. Carlos Taxonera

  172. Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: A comparative analysis of nine scoring methods

    Article • Scandinavian Journal of Gastroenterology, December 2009, Taylor & Francis

    MD. PhD. Carlos Taxonera

  173. Infliximab Maintenance Therapy Is Associated With Decreases in Direct Resource Use in Patients With Luminal or Fistulizing Crohnʼs Disease

    Article • Journal of Clinical Gastroenterology, November 2009, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  174. Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: A Study in the Spanish population and a meta-analysis

    Article • Inflammatory Bowel Diseases, November 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  175. Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility

    Article • Genes & Immunity, August 2009, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  176. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

    Article • Inflammatory Bowel Diseases, August 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  177. Novel Association of the Interleukin 2–Interleukin 21 Region With Inflammatory Bowel Disease

    Article • The American Journal of Gastroenterology, May 2009, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  178. 559 Fertility and Outcomes of Pregnancies Fathered By Male Patients Exposed to Thiopurines

    Article • Gastroenterology, May 2009, Elsevier

    MD. PhD. Carlos Taxonera

  179. S1098 Patient Preferences for Crohn's Disease: A Discrete Choice Experiment in Flare-Up and Maintenance Therapy

    Article • Gastroenterology, May 2009, Elsevier

    MD. PhD. Carlos Taxonera

  180. S1140 Infliximab Maintenance Therapy Decreases Productivity Loss and Direct Resource Use in Patients with Crohn's Disease or Ulcerative Colitis

    Article • Gastroenterology, May 2009, Elsevier

    MD. PhD. Carlos Taxonera

  181. S1165 Unexpected Follow-Up Surgeries Related to Failures in Colectomy for Ulcerative Colitis

    Article • Gastroenterology, May 2009, Elsevier

    MD. PhD. Carlos Taxonera

  182. S1168 Postcolectomy Burden in Ulcerative Colitis Patients Undergoing Colectomy

    Article • Gastroenterology, May 2009, Elsevier

    MD. PhD. Carlos Taxonera

  183. S1199 Analysis of Non-Synonymous Single Nucleotide Polymorphism At Diamine Oxidase Gene (Refsnp ID: Rs1049793) in Patients with Crohn's Disease

    Article • Gastroenterology, May 2009, Elsevier

    MD. PhD. Carlos Taxonera

  184. Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15− Crohn's disease patients

    Article • European Journal of Human Genetics, April 2009, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  185. CIRUGÍAS NO PROGRAMADAS DEBIDAS A FRACASOS EN LA COLECTOMÍA POR COLITIS ULCEROSA

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  186. COLECTOMÍA DEBIDA A COLITIS ULCEROSA: CIRUGÍAS FINALES Y TIEMPOS

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  187. EFICACIA Y SEGURIDAD DEL METOTREXATO EN LA ENFERMEDAD INFLAMATORIA INTESTINAL: EXPERIENCIA DEL GRUPO DE MADRID

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  188. EL TRATAMIENTO DE MANTENIMIENTO CON INFLIXIMAB REDUCE LA PÉRDIDA DE PRODUCTIVIDAD Y EL CONSUMO DE RECURSOS DIRECTOS EN LOS PACIENTES CON ENFERMEDAD DE CROHN Y COLITIS ULCEROSA

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  189. MOTIVOS PARA LA COLECTOMÍA EN PACIENTES CON COLITIS ULCEROSA EN LA ERA DE LOS INMUNOMODULADORES

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  190. UTILIDAD DE LA CALPROTECTINA Y LACTOFERRINA FECAL EN LA PREDICCIÓN DE LA RECIDIVA DE LA ENFERMEDAD INFLAMATORIA INTESTINAL (EII)

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  191. VALORACIÓN DE LA FIBROSIS HEPÁTICA MEDIANTE ELASTOGRAFÍA HEPÁTICA (FIBROSCAN) EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII) TRATADOS CON METOTREXATO (MTX)

    Article • Gastroenterología y Hepatología, March 2009, Elsevier

    MD. PhD. Carlos Taxonera

  192. P025 - Patient preferences for Crohn's disease maintenance therapy: a discrete choice experiment

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  193. P039 - Faecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  194. P078 - Patient preferences for Crohn's disease flare-up therapy: a discrete choice experiment

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  195. P196 - Fertility and outcomes of pregnancies fathered by male patients exposed to thiopurines

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  196. P215 - Novel association of the interleukin 2 interleukin 21 region with inflammatory bowel disease

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  197. P235 - Analysis of non-synonymous single nucleotide polymorphism at diamine oxidase gene (refSNP Id: Rs1049793) in patients with Crohn's disease

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  198. P259 - An FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease

    Article • Journal of Crohn s and Colitis, February 2009, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  199. Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease

    Article • Scandinavian Journal of Gastroenterology, January 2009, Taylor & Francis

    MD. PhD. Carlos Taxonera

  200. Emerging treatments for complex perianal fistula in Crohn’s disease

    Article • World Journal of Gastroenterology, January 2009, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    MD. PhD. Carlos Taxonera

  201. PG134 PATIENT PREFERENCES FOR CROHN'S DISEASE MAINTENANCE THERAPY: A DISCRETE CHOICE EXPERIMENT

    Article • Value in Health, November 2008, Elsevier

    MD. PhD. Carlos Taxonera

  202. PG135 PATIENT PREFERENCES FOR CROHN'S DISEASE FLARE-UP THERAPY: A DISCRETE CHOICE EXPERIMENT

    Article • Value in Health, November 2008, Elsevier

    MD. PhD. Carlos Taxonera

  203. Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto

    Article • Revista Española de Enfermedades Digestivas, November 2008, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  204. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis

    Article • Alimentary Pharmacology & Therapeutics, September 2008, Wiley

    MD. PhD. Carlos Taxonera

  205. IL23R and IL12B polymorphisms in spanish IBD patients: No evidence of interaction

    Article • Inflammatory Bowel Diseases, September 2008, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  206. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

    Article • Gastroenterología y Hepatología, July 2008, Elsevier

    MD. PhD. Carlos Taxonera

  207. M1141 Infliximab Maintenance Therapy Decreases the Use of Non-Pharmacological Resources in Patients with Crohn's Disease

    Article • Gastroenterology, April 2008, Elsevier

    MD. PhD. Carlos Taxonera

  208. S1185 Faecal Calprotectin's Utility in the Prediction of Inflammatory Bowel Disease (IBD) Relapses

    Article • Gastroenterology, April 2008, Elsevier

    MD. PhD. Carlos Taxonera

  209. P041 INFLIXIMAB IMPACT ON THE USE OF HEALTH CARE RESOURCES AMONG PATIENTS WITH CROHN'S DISEASE IN CLINICAL PRACTICE CONDITIONS

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  210. P074 ACUTE PANCREATITIS IN INFLAMMATORY BOWEL DISEASE

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  211. P100 FAECAL CALPROTECTIN'S UTILITY IN THE PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) RELAPSES

    Article • Journal of Crohn s and Colitis Supplements, February 2008, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  212. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding

    Article • Pharmacogenetics and Genomics, January 2008, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera

  213. CD209 in inflammatory bowel disease: a case-control study in the Spanish population

    Article • BMC Medical Genetics, December 2007, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  214. Role of the PXR gene locus in inflammatory bowel diseases

    Article • Inflammatory Bowel Diseases, December 2007, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  215. Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility

    Article • Immunogenetics, October 2007, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  216. Prevalencia de la infección por Helicobacter pylori en población sana en la Comunidad de Madrid

    Article • Revista Española de Enfermedades Digestivas, September 2007, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  217. Utilidad de la biopsia hepática en el diagnóstico etiológico de las alteraciones de la analítica hepática de causa incierta

    Article • Gastroenterología y Hepatología, June 2007, Elsevier

    MD. PhD. Carlos Taxonera

  218. GSTT1andGSTM1Null Genotypes May Facilitate Hepatitis C Virus Infection Becoming Chronic

    Article • The Journal of Infectious Diseases, May 2007, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  219. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohnʼs disease

    Article • Inflammatory Bowel Diseases, May 2007, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  220. MYO9B polymorphisms in patients with inflammatory bowel disease

    Article • Gut, April 2007, BMJ

    MD. PhD. Carlos Taxonera

  221. Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD

    Article • Tissue Antigens, April 2007, Wiley

    MD. PhD. Carlos Taxonera

  222. Crohn’s Disease

    Article • Drugs, January 2007, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  223. Polymorphisms in the interleukin-10 gene and relation to phenotype in patients with ulcerative colitis

    Article • Revista Española de Enfermedades Digestivas, February 2006, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  224. MDR1 gene: Susceptibility in Spanish Crohnʼs disease and ulcerative colitis patients

    Article • Inflammatory Bowel Diseases, January 2006, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  225. Polymorphisms in interleukin-10 gene according to mutations ofNOD2/CARD15gene and relation to phenotype in Spanish patients with Crohn’s disease

    Article • World Journal of Gastroenterology, January 2006, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    MD. PhD. Carlos Taxonera

  226. Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene

    Article • World Journal of Gastroenterology, January 2006, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    MD. PhD. Carlos Taxonera

  227. Sa.144. Epistatic Interaction Between FCRl3 and MHC in UC Spanish Patients

    Article • Clinical Immunology, January 2006, Elsevier

    MD. PhD. Carlos Taxonera

  228. Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population

    Article • European Journal of Human Genetics, December 2005, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  229. A computer-assisted morphometric quantitative analysis of iron overload in liver biopsies. A comparison with histological and biochemical methods

    Article • Pathology - Research and Practice, October 2005, Elsevier

    MD. PhD. Carlos Taxonera

  230. A Recombined Haplotype in the Major Histocompatibility Region Contains a Cluster of Genes Conferring High Susceptibility to Ulcerative Colitis in the Spanish Population

    Article • Inflammatory Bowel Diseases, September 2005, Oxford University Press (OUP)

    MD. PhD. Carlos Taxonera

  231. Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal: diferencias entre la enfermedad de Crohn y la colitis ulcerosa

    Article • Medicina Clínica, September 2005, Elsevier

    MD. PhD. Carlos Taxonera

  232. Clinical value of gene NOD2/CARD15 mutations in Crohn's disease

    Article • Revista Española de Enfermedades Digestivas, August 2005, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  233. IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab

    Article • World Journal of Gastroenterology, January 2005, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    MD. PhD. Carlos Taxonera

  234. Diagnostic and treatment recommendations on perianal Crohn's disease

    Article • Revista Española de Enfermedades Digestivas, January 2005, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  235. Colorectal cancer and Coxibs

    Article • Revista Española de Enfermedades Digestivas, October 2004, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  236. Consumo de lácteos y enfermedad inflamatoria intestinal: ¿invertir la tendencia?

    Article • Anales de Medicina Interna, May 2004, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  237. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use

    Article • British Journal of Pharmacology, January 2004, Wiley

    MD. PhD. Carlos Taxonera

  238. Esofagitis de etiolog?a infecciosa y t?xica/c?ustica

    Article • Medicine - Programa de Formación Médica Continuada Acreditado, January 2004, Elsevier

    MD. PhD. Carlos Taxonera

  239. Uso inapropiado de antisecretores en el medio hospitalario

    Article • Anales de Medicina Interna, November 2002, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  240. Infección diseminada y severa por citomegalovirus en paciente inmunocompetente

    Article • Anales de Medicina Interna, May 2002, Instituto de Salud Carlos III/BNCS/SciELO Espana

    MD. PhD. Carlos Taxonera

  241. Topical anesthesia and urease tests

    Article • Gastrointestinal Endoscopy, December 1996, Elsevier

    MD. PhD. Carlos Taxonera

  242. Simultaneous two-level esophageal 24-hour pH monitoring in patients with mild and severe esophagitis

    Article • Digestive Diseases and Sciences, July 1995, Springer Science + Business Media

    MD. PhD. Carlos Taxonera

  243. Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers

    Article • The American Journal of Medicine, August 1991, Elsevier

    MD. PhD. Carlos Taxonera